The frequency of adverse reactions reported in placebo-controlled trials after a single administration is defined as follows: Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data).
The following adverse reactions were seen in patients treated across a variety of indications including blepharospasm, hemifacial spasm, torticollis, spasticity associated with either cerebral palsy or stroke/TBI and axilliary hyperhidrosis: see Table 13.

Frequency of specific adverse reactions by indication: In addition, the following adverse reactions specific to individual indications were reported: see Tables 14, 15, 16 and 17.




Focal spasticity of upper and lower limbs in paediatric cerebral palsy patients, two years of age or older: When treating upper and lower limbs concomitantly with Dysport at a total dose of up to 30 U/kg or 1000 U whichever is lower, there are no safety findings in addition to those expected from treating either upper limb or lower limb muscles alone. (See Table 18.)

Dysphagia appeared to be dose related and occurred most frequently following injection into the sternomastoid muscle. A soft diet may be required until symptoms resolve. These side effects may be expected to resolve within two to four weeks. (See Table 19.)

Side effects may occur due to deep or misplaced injections of Dysport temporarily paralysing other nearby muscle groups. (See Tables 20, 21 and 22.)



Post-marketing experience: see Table 23.

View ADR Reporting Link